Amikacin liposomal inhaled - Insmed

Drug Profile

Amikacin liposomal inhaled - Insmed

Alternative Names: Amikacin sustained release; Arikace; ARIKAYCE; Liposomal amikacin for inhalation; SLIT™ Amikacin

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Transave
  • Developer Insmed; National Institute of Allergy and Infectious Diseases; Oregon Health & Science University; University of Texas Health Science Center at Tyler
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections; Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cystic fibrosis-associated respiratory tract infections; Mycobacterial infections
  • Phase II Bronchiectasis

Most Recent Events

  • 14 Feb 2017 Insmed receives patent covering amikacin liposomal inhalation for Infections (Pulmonary) in USA
  • 03 Nov 2016 Insmed completes enrolment in the CONVERT phase III trial for Mycobacterial infection in USA, Australia, Austria, France, Germany, New Zealand, Canada, Netherlands, Italy, Spain, United Kingdom, Japan and Poland
  • 18 Oct 2016 Adverse events and efficacy data from a phase II trial in Mycobacterial infection released by Insmed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top